The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells
2009

Cilengitide's Effects on Endothelial Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): Alghisi Gian Carlo, Ponsonnet Lionel, Rüegg Curzio

Primary Institution: University of Lausanne

Hypothesis

Does cilengitide affect endothelial cells expressing αVβ3 but adhering through β1 integrins?

Conclusion

Cilengitide disrupts VE-cadherin localization and increases permeability in endothelial cells.

Supporting Evidence

  • Cilengitide activates αVβ3 and disrupts VE-cadherin localization.
  • Cilengitide increases permeability of endothelial cell monolayers.
  • Cilengitide induces phosphorylation of Src, FAK, and VE-cadherin.
  • Cilengitide interferes with β1 integrin-mediated adhesion.
  • Cilengitide causes endothelial cell detachment on low-density ligands.

Takeaway

Cilengitide is a drug that can make blood vessel cells leakier by messing with their connections.

Methodology

The study used morphological, biochemical, pharmacological, and functional approaches to investigate cilengitide's effects on human umbilical vein endothelial cells (HUVEC).

Limitations

The study primarily focuses on in vitro conditions, which may not fully replicate in vivo environments.

Participant Demographics

Human umbilical vein endothelial cells (HUVEC) were used.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0004449

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication